PMID- 15363202
OWN - NLM
STAT- MEDLINE
DCOM- 20050209
LR  - 20171116
VI  - 23
IP  - 9
DP  - 2004 Sep
TI  - [Clinical significance of quantitative analysis of serum VEGF, CD44s, and MMP-3 
      protein in nasopharyngeal carcinoma].
PG  - 1060-4
AB  - BACKGROUND & OBJECTIVE: Increasing evidences showed that circulating tumor 
      metastasis related factors could be detected, and it is related to tumor stage, 
      and prognosis. This study was to investigate the correlation of serum vascular 
      endothelial growth factor (sVEGF), CD44 standard (CD44s), and matrix 
      metalloproteinase-3 (MMP-3) level to the clinical outcomes in nasopharyngeal 
      carcinoma (NPC)patients. METHODS: Forty-six NPC patients without metastasis, 20 
      NPC patients with local recurrence and/or distant metastasis,and 28 healthy 
      controls entered this study. Serum VEGF, CD44s, and MMP-3 protein were 
      quantitatively analyzed by enzyme-link immunosorbent assay (ELISA). RESULTS: The 
      mean level of sVEGF in metastatic NPC was (791.7+/-560.5) ng/L, which was 
      significantly higher than that in NPC patients without metastasis 
      [(429.0+/-249.7) ng/L], and healthy controls [(424.6+/-197.1) ng/L], whereas 
      there was no significant difference between NPC patients without metastasis and 
      healthy controls. In primary NPC patients, sVEGF level in NPC of stage T4 were 
      significantly higher than those in NPC of stage T1-T3. Moreover, 2-year 
      disease-free survival rate in patients with sVEGF level of more than 600 ng/L was 
      significantly lower than that in patients with sVEGF Level of less than 600 ng/L 
      (37.5% vs 83.9%). The serum level of MMP-3 in NPC patients with metastasis 
      [(28.8+/-15.5)microg/L] was significantly higher than that in patients without 
      metastasis [(19.8+/-11.6) microg/L], and healthy controls [(16.2+/-11.1) 
      microg/L], but there was no significant difference between NPC patients without 
      metastasis and healthy controls. Though the serum level of CD44s in NPC patients 
      (including patients with or without metastasis) was higher than that in healthy 
      controls, there was no significant difference between NPC patients with and 
      without metastasis. No correlation was observed between serum MMP-3, CD44s level 
      and clinical outcomes of NPC. CONCLUSION: Our results indicate that when the 
      sVEGF level are >or= 800 ng/L and/or serum MMP-3 level >or= 30 microg/L in NPC 
      patients, local recurrence or distant metastasis would occur. In primary NPC 
      patients without metastasis, sVEGF level is correlate with primary tumor 
      progression, moreover, sVEGF level of >or= 600 ng/L before treatment predicate 
      lower 2-year disease-free survival rate.
FAU - Li, Yu-Hong
AU  - Li YH
AD  - Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, 
      Guangdong, 510060, PR China.
FAU - Shao, Jian-Yong
AU  - Shao JY
FAU - Li, Su
AU  - Li S
FAU - Zou, Ben-Yan
AU  - Zou BY
FAU - Huang, Hui-Qiang
AU  - Huang HQ
FAU - Guan, Zhong-Zhen
AU  - Guan ZZ
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Hyaluronan Receptors/*blood
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/*blood/pathology
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2004/09/15 05:00
MHDA- 2005/02/11 09:00
CRDT- 2004/09/15 05:00
PHST- 2004/09/15 05:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/09/15 05:00 [entrez]
AID - 1000467X2004091060 [pii]
PST - ppublish
SO  - Ai Zheng. 2004 Sep;23(9):1060-4.